Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years

NCT01193400 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT01193400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01193400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2010
Completion date
February 29, 2012
Enrollment
75 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia